Nov 16 (Reuters) - Shares of Summit Therapeutics fell nearly 20% in premarket trading on Monday after the US Food and Drug Administration declined to approve its experimental lung cancer drug …

Get live updates on this topic:
Silent notifications:
Interval of time threshold:
Get live updates on this topic:
Silent notifications:
Interval of time threshold:
We will only send you breaking news updates, and your own specified custom filters notifications.